WST on NYSE
West Pharmaceutical Services (United States)
Logo: Unknown author Unknown author, Public domain, via Wikimedia Commons5
.svg){kind=link}
American healthcare company
West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. Founded in 1923 by Herman O. West and J.R. Wike of Philadelphia, the company is headquartered in Exton, Pennsylvania. In its early years of development, West produced rubber components for packaging injectable drugs, providing a sterile environment for the producers of penicillin and insulin.3 Its shares trade on NYSE under the symbol WST.1 Wikipedia text CC BY-SA 4.0
Price unavailable
Last updated Oct 20, 2026.
Overview
Compare with MiniMed Group, Inc., Globus Medical or Insulet (United States), or pick any stock.
- TickerWST on NYSE1
- IndustrySurgical & Medical Instruments & Apparatus1
- HeadquartersExton1
- Websitewww.westpharma.com/en/Pages/Default.aspx
- Incorporated inPA6
- Business address530 Herman O. West Drive, Exton, Pa 193416
- Filer categoryLarge accelerated filer6
- Legal formBusiness Corporation4
- LEI5493007NKRGM1RJQ1P164
- StatusActive4
- LEI statusIssued and current4
- Registered addressC/O CORPORATION SERVICE COMPANY, 19341 Exton, United States4
- Registered withPennsylvania Department of State, 3846594
See how the biggest companies compare on our leaderboards
West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. Founded in 1923 by Herman O. West and J.R. Wike of Philadelphia, the company is headquartered in Exton, Pennsylvania. In its early years of development, West produced rubber components for packaging injectable drugs, providing a sterile environment for the producers of penicillin and insulin.3
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue64¢$2.0B
- Research and development2¢$74.3M
- Selling, general and admin13¢$393.6M
- Other costs1¢$20.8M
- Income tax4¢$121.6M
- Profit16¢$493.7M
Out of $3.1B in revenue.9
Where each dollar of operating cash went, fiscal 2025
- Capital spending38¢$285.9M
- Dividends paid8¢$61.2M
- Share buybacks18¢$134.0M
- Kept or used elsewhere36¢$273.7M
Out of $754.8M of cash from operations.9
Financial statements
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $1.8B10 | $2.1B11 | $2.8B12 | $2.9B13 | $2.9B9 | $2.9B9 | $3.1B9 |
| Cost of revenue | $1.2B10 | $1.4B11 | $1.7B12 | $1.8B13 | $1.8B9 | $1.9B9 | $2.0B9 |
| Gross profit | $605.7M10 | $767.8M11 | $1.2B12 | $1.1B13 | $1.1B9 | $998.5M9 | $1.1B9 |
| Research and development | $38.9M10 | $46.9M11 | $52.8M12 | $58.5M13 | $68.4M9 | $69.1M9 | $74.3M9 |
| Selling, general and admin | $272.7M10 | $302.0M11 | $362.8M12 | $316.9M13 | $353.4M9 | $338.5M9 | $393.6M9 |
| Operating income | $296.6M10 | $406.9M11 | $752.3M12 | $734.0M13 | $676.0M9 | $569.9M9 | $584.9M9 |
| Interest | $8.5M10 | $8.2M11 | $8.2M12 | $7.9M12 | $9.0M12 | ||
| Income before tax | $748.9M12 | $679.9M13 | $698.0M9 | $585.5M9 | $600.9M9 | ||
| Income tax | $59.0M10 | $72.5M11 | $107.2M12 | $114.7M13 | $122.3M9 | $107.5M9 | $121.6M9 |
| Net income | $241.7M10 | $346.2M11 | $661.8M12 | $585.9M13 | $593.4M9 | $492.7M9 | $493.7M9 |
| Earnings per share | $3.2710 | $4.6811 | $8.8912 | $7.8713 | $7.989 | $6.759 | $6.839 |
| Earnings per share (diluted) | $3.2110 | $4.5711 | $8.6712 | $7.7313 | $7.889 | $6.699 | $6.799 |
| Shares (weighted, basic) | 74.4M shares12 | 74.4M shares13 | 74.3M shares9 | 73.0M shares9 | 72.3M shares9 | ||
| Shares (weighted, diluted) | 76.3M shares12 | 75.8M shares13 | 75.3M shares9 | 73.7M shares9 | 72.7M shares9 |
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash | $439.1M10 | $615.5M10 | $762.6M11 | $894.3M12 | $853.9M13 | $484.6M9 | $791.3M9 |
| Receivables | $489.0M11 | $507.4M12 | $512.0M13 | $552.5M9 | $574.4M9 | ||
| Inventory | $378.4M11 | $414.8M12 | $434.7M13 | $377.0M9 | $443.9M9 | ||
| Current assets | $1.1B16 | $1.4B10 | $1.7B11 | $1.9B12 | $1.9B13 | $1.5B9 | $2.0B9 |
| Property, plant and equipment | $1.1B11 | $1.2B12 | $1.4B13 | $1.6B9 | $1.7B9 | ||
| Goodwill | $109.9M12 | $107.3M13 | $108.5M9 | $106.0M9 | $109.9M9 | ||
| Intangible assets | $23.0M11 | $18.4M12 | $15.1M13 | $10.8M9 | $7.7M9 | ||
| Total assets | $2.3B16 | $2.8B10 | $3.3B11 | $3.6B12 | $3.8B13 | $3.6B9 | $4.3B9 |
| Accounts payable | $232.2M11 | $215.4M12 | $242.4M13 | $239.3M9 | $253.7M9 | ||
| Short-term debt | $44.2M11 | $2.2M12 | $134.0M13 | $09 | $09 | ||
| Current liabilities | $341.6M16 | $503.4M10 | $594.1M11 | $519.0M12 | $671.8M13 | $550.4M9 | $654.9M9 |
| Long-term debt | $255.0M16 | $252.9M10 | $208.8M11 | $206.7M12 | $72.8M13 | $202.6M9 | $202.8M9 |
| Total liabilities | $768.2M16 | $939.3M10 | $978.4M11 | $931.9M12 | $948.5M13 | $961.1M9 | $1.1B9 |
| Retained earnings | $2.5B11 | $3.0B12 | $3.5B13 | $4.0B9 | $4.4B9 | ||
| Shareholders’ equity | $1.6B11 | $1.9B12 | $2.3B13 | $2.7B9 | $2.9B9 | $2.7B9 | $3.2B9 |
| Shares outstanding | 74.1M shares16 | 74.0M shares10 | 74.2M shares11 | 74.1M shares12 | 73.5M shares13 | 72.3M shares9 | 72.0M shares9 |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash from operations | $367.2M10 | $472.5M11 | $584.0M12 | $724.0M13 | $776.5M9 | $653.4M9 | $754.8M9 |
| Depreciation and amortization | $122.3M12 | $120.6M13 | $137.3M9 | $155.4M9 | $171.4M9 | ||
| Stock-based compensation | $37.5M12 | $23.7M13 | $23.3M9 | $18.7M9 | $23.8M9 | ||
| Capital spending | $126.4M10 | $174.4M11 | $253.4M12 | $284.6M13 | $362.0M9 | $377.0M9 | $285.9M9 |
| Free cash flow | $240.8M | $298.1M | $330.6M | $439.4M | $414.5M | $276.4M | $468.9M |
| Cash from investing | -$253.1M12 | -$288.2M13 | -$368.7M9 | -$378.7M9 | -$285.9M9 | ||
| Dividends paid | $45.1M10 | $48.1M11 | $51.1M12 | $54.1M13 | $57.0M9 | $59.1M9 | $61.2M9 |
| Share buybacks | $83.1M10 | $115.5M11 | $137.1M12 | $202.8M13 | $438.3M9 | $560.9M9 | $134.0M9 |
| Cash from financing | -$168.1M12 | -$293.6M13 | -$459.6M9 | -$622.6M9 | -$185.1M9 | ||
| Dividend per share | $0.6210 | $0.6611 | $0.7012 | $0.7413 | $0.789 | $0.829 | $0.869 |
Compare West Pharmaceutical Services (United States) with another company
Corporate structure
West Pharmaceutical Services (United States) sits at the top of its group. 44 entities, 21 countries on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of West Pharmaceutical Services (United States)
- FMR LLC Filed SCHEDULE 13G on West Pharmaceutical Services (United States), latest Aug 6, 2026
- VANGUARD CAPITAL MANAGEMENT LLC Filed SCHEDULE 13G on West Pharmaceutical Services (United States), latest Apr 30, 2026
- VANGUARD PORTFOLIO MANAGEMENT LLC Filed SCHEDULE 13G on West Pharmaceutical Services (United States), latest Apr 29, 2026
- VANGUARD GROUP INC Filed SCHEDULE 13G/A on West Pharmaceutical Services (United States), latest Mar 27, 2026 (5 filings since Feb 10, 2022)
- PRICE T ROWE ASSOCIATES INC /MD/ Filed SC 13G/A on West Pharmaceutical Services (United States), latest Feb 14, 2023 (2 filings since Feb 14, 2022)
- Franklin Templeton Investments Filed SC 13G/A on West Pharmaceutical Services (United States), latest Feb 4, 2022
- West Pharmaceutical Services (United States) Exton, Pennsylvania, United States
- WEST PHARMACEUTICAL SERVICES HOLDING GMBH Eschweiler, Germany
- West Pharmaceutical Services Deutschland Subsidiary · Eschweiler, Germany
- Tech Group Europe Limited Subsidiary · Ireland
- Tech Group Grand Rapids, Inc. Subsidiary · Delaware, United States
- TGPR HOLDINGS LIMITED Subsidiary · Dublin, Ireland
- West Contract Manufacturing, LLC Subsidiary · Delaware, United States
- WEST PHARMA. SERVICES IL, LTD. (ווסט פארמה סרוויסס איי אל, בע"מ) Subsidiary · Ra'Anana, Israel
- West Pharmaceutical Packaging (China) Company Ltd. Subsidiary · China
- WEST PHARMACEUTICAL PACKAGING INDIA PRIVATE LIMITED Subsidiary · Hyderabad, India
- West Pharmaceutical Products Ireland, Ltd. Subsidiary · Ireland
- West Pharmaceutical Services Argentina S.A. Subsidiary · Argentina
- West Pharmaceutical Services Asia, Ltd. Subsidiary · Taiwan
- West Pharmaceutical Services Australia Pty. Ltd. Subsidiary · Australia
- West Pharmaceutical Services AZ, Inc. Subsidiary · Arizona, United States
- West Pharmaceutical Services Beograd d.o.o. Subsidiary · Serbia
- West Pharmaceutical Services Brasil Ltda. Subsidiary · Brazil
- West Pharmaceutical Services Colombia S.A.S. Subsidiary · Colombia
- West Pharmaceutical Services Cornwall Limited Subsidiary · United Kingdom
- West Pharmaceutical Services Danmark ApS Subsidiary · Denmark
- West Pharmaceutical Services Delaware Acquisition, Inc. Subsidiary · Delaware, United States
- West Pharmaceutical Services Deutschland GmbH & Co. KG Subsidiary · Germany
- West Pharmaceutical Services European Holdings 1 GmbH Subsidiary · Germany
- West Pharmaceutical Services European Holdings II GmbH Subsidiary · Germany
- West Pharmaceutical Services France S.A. Subsidiary · France
- West Pharmaceutical Services Group Limited Subsidiary · United Kingdom
- and 18 more
Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; subsidiaries, stakes and holdings from Wikidata (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What West Pharmaceutical Services (United States) reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $3.2B9 Dec 31, 2025 | $3.0B9 Dec 31, 2024 | +8.0% |
| Accumulated depreciation | $1.5B9 Dec 31, 2025 | $1.4B9 Dec 31, 2024 | +6.6% |
| Property and equipment, net | $1.7B9 Dec 31, 2025 | $1.6B9 Dec 31, 2024 | +9.2% |
| Finance-lease assets | $34.7M9 Dec 31, 2025 | $29.7M9 Dec 31, 2024 | +16.8% |
| Operating-lease assets (leased space) | $117.0M9 Dec 31, 2025 | $104.5M9 Dec 31, 2024 | +12.0% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $791.3M9 Dec 31, 2025 | $484.6M9 Dec 31, 2024 | +63.3% |
| Stakes in other companies (equity method) | $208.3M9 Dec 31, 2025 | $194.9M9 Dec 31, 2024 | +6.9% |
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Goodwill | $109.9M9 Dec 31, 2025 | $106.0M9 Dec 31, 2024 | +3.7% |
| Intangible assets, net (excluding goodwill) | $7.7M9 Dec 31, 2025 | $10.8M9 Dec 31, 2024 | −28.7% |
| Finite-lived intangibles, gross | $76.3M9 Dec 31, 2025 | $76.1M9 Dec 31, 2024 | +0.3% |
| Accumulated amortization | $68.6M9 Dec 31, 2025 | $65.3M9 Dec 31, 2024 | +5.1% |
| Finite-lived intangibles, net | $7.7M9 Dec 31, 2025 | $10.8M9 Dec 31, 2024 | −28.7% |
Inventory
| Item | Latest | A year before | Change |
|---|---|---|---|
| Inventory, total | $443.9M9 Dec 31, 2025 | $377.0M9 Dec 31, 2024 | +17.7% |
| Raw materials | $163.2M9 Dec 31, 2025 | $166.9M9 Dec 31, 2024 | −2.2% |
| Work in process | $103.2M9 Dec 31, 2025 | $65.2M9 Dec 31, 2024 | +58.3% |
| Finished goods | $177.5M9 Dec 31, 2025 | $144.9M9 Dec 31, 2024 | +22.5% |
Properties, in its own words
Our corporate headquarters are located at 530 Herman O. West Drive, Exton, Pennsylvania 19341.
The following table summarizes our facilities by segment and geographic region. All facilities shown are owned except where otherwise noted.
The rest of Item 2
Type of Facility/ Country · Location · Segment
Manufacturing:
United States of America · Scottsdale, AZ (1) (2) · Proprietary Products
Tempe, AZ (2) · Proprietary Products and Contract Manufactured Products
St. Petersburg, FL (1) · Proprietary Products
Greenfield, IN (2) · Contract Manufactured Products
Grand Rapids, MI · Contract Manufactured Products
Kinston, NC · Proprietary Products
Kearney, NE · Proprietary Products
Jersey Shore, PA · Proprietary Products
Williamsport, PA · Proprietary Products and Contract Manufactured Products
Cayey, Puerto Rico · Proprietary Products and Contract Manufactured Products
South America
Brazil · Sao Paulo · Proprietary Products
Europe
Denmark · Horsens · Proprietary Products
England · St. Austell · Proprietary Products
France · Le Nouvion · Proprietary Products
Germany · Eschweiler (1) (2) · Proprietary Products
Stolberg · Proprietary Products
Ireland · Waterford · Proprietary Products
Dublin (1) (2) · Contract Manufactured Products
Serbia · Kovin · Proprietary Products
Asia Pacific
China · Qingpu · Proprietary Products
India · Sri City · Proprietary Products
Singapore · Jurong (1) (2) · Proprietary Products
Type of Facility/ Country · Location · Segment
Mold-and-Die Tool Shop:
United States of America · Upper Darby, PA · Proprietary Products
Europe
England · Bodmin · Proprietary Products
Germany · Stolberg · Proprietary Products
Contract Analytical Laboratory:
United States of America · Exton, PA · Proprietary Products
Technology Center:
Asia Pacific
India · Bangalore (1) (2) · Proprietary Products and Contract Manufactured Products
(1)This manufacturing facility is also used for research and development activities.
(2)This facility is leased in whole or in part.
Our Proprietary Products reportable segment leases facilities located in Scottsdale, AZ, Radnor, PA, Germany, Israel and Taiwan for research and development, as well as other activities. Sales offices in various locations are leased under contractual arrangements.
Item 2 of the 10-K filed Feb 17, 2026.17
Leadership
Who has led West Pharmaceutical Services (United States), and when. Pick a name to see everywhere that person has worked.
President
Chief financial officer
Chief operating officer
- Chief executive officerMichel Lagarde Sep 10, 2026 to now18
- Chief executive officerEric Mark Green Apr 27, 2015 to Sep 10, 202619
- Chief executive officerDonald E. Morel Jr. Jan 3, 2006 to Jul 1, 201520
- ChairEric Mark Green Dec 8, 2023 to now21
- ChairDonald E. Morel Jr. Jan 3, 2006 to Jul 1, 201520
- PresidentMichel Lagarde Sep 10, 2026 to now18
- PresidentEric Mark Green Sep 12, 2016 to Sep 10, 202622
- PresidentChristopher G. Ryan Feb 24, 2015 to Feb 25, 201623
- PresidentKaren Flynn Jul 6, 2012 to Aug 29, 201624
- PresidentWarwick Bedwell Aug 9, 2012 to Feb 25, 201625
- PresidentJohn E. Paproski Feb 23, 2010 to Feb 25, 201626
- PresidentHeino Lennartz Jul 16, 2009 to Mar 14, 201627
- PresidentSteven A. Ellers Jan 3, 2006 to Feb 24, 201128
- PresidentDonald A. McMillan Feb 28, 2006 to Jun 15, 201229
- PresidentRobert S. Hargesheimer Sep 6, 2006 to Aug 26, 200930
- Chief financial officerRobert W. McMahon Aug 12, 2025 to now31
- Chief financial officerBernard Birkett Jun 25, 2018 to Feb 20, 202532
- Chief financial officerWilliam J. Federici Jan 3, 2006 to Jun 11, 201833
- Chief operating officerBernard Birkett May 25, 2022 to Mar 22, 202334
- Chief operating officerMatthew T. Mullarkey Jul 29, 2008 to Dec 15, 200935
- Chief operating officerSteven A. Ellers Jan 3, 2006 to Feb 24, 201128
Board members and other officers (44)
- SVP, Strategy & Corporate DevRodolphe Jean Poussot Aug 1, 2025 to now36
- SVP, GC & Corporate SecretaryNorman D. Finch Jr. Dec 10, 2025 to now37
- Sr VP, Chief Fin & Ops OffBernard Birkett Aug 8, 2023 to Feb 22, 202438
- Senior Vice PresidentCindy Reiss-Clark Mar 23, 2022 to Feb 20, 202539
- VP & TreasurerCharles Witherspoon Apr 12, 2022 to now40
- VP, CAO & Corporate ControllerChad Winters May 7, 2020 to now41
- SVP, GC & Corporate SecretaryKimberly Banks Mackay Dec 22, 2020 to Feb 20, 202542
- Chief Digital & Trans OfficerSilji Abraham Feb 28, 2018 to Oct 31, 202443
- VP Corp Development & StrategyQuintin J. Lai Aug 1, 2018 to Feb 22, 202444
- Sr VP & Chief Commercial OfficKaren Flynn Sep 7, 2016 to Feb 21, 201945
- SVP, Glob Ops and Supply ChainDavid A. Montecalvo Sep 28, 2016 to Feb 24, 202246
- Sr. VP Human Resources OfficerAnnette F. Favorite Oct 7, 2015 to now47
- Sr. VP, GC & Corp. Sec.George Lloyd Miller Nov 23, 2015 to Nov 9, 202048
- VP, Deputy Gen Coun & Corp SecRachael M. Bushey Oct 22, 2013 to Feb 26, 201449
- VP Pharma Pckg SystemsJeffrey C. Hunt Jan 6, 2011 to Feb 26, 201450
- VP Pharma Pkgs Systems Asia PaWarwick Bedwell Jan 6, 2011 to Feb 23, 201251
- Pres., Europe & Asia PacificFabio De Sampaio Doria Filho Jan 5, 2009 to Feb 26, 200952
- Vice President - InnovationsJohn E. Paproski Jan 19, 2007 to Mar 6, 200953
- VP, Gen. Counsel & Sec.John R. Gailey Jan 3, 2006 to Feb 23, 201554
- VP & Chief Compliance OfficerLinda R. Altemus Jan 3, 2006 to Jan 30, 200655
- Vice President and TreasurerMichael A. Anderson Jan 3, 2006 to Mar 2, 201656
- VP, Human ResourcesRichard D. Luzzi Jan 3, 2006 to Feb 27, 201557
- Corporate ControllerJoseph E. Abbott Feb 28, 2006 to Mar 1, 201158
- Div Pres-Pharma Device GroupRobert S. Hargesheimer Feb 28, 2006 to Sep 1, 200659
- Board memberMichel Lagarde Sep 10, 2026 to now18
- Board memberJanet Brutschea Haugen Dec 18, 2024 to now60
- Board memberStephen H. Lockhart Aug 2, 2022 to now61
- Board memberMolly Joseph Aug 24, 2021 to now62
- Board memberDeborah L. Tanner Jun 1, 2017 to now63
- Board memberEric Mark Green Apr 26, 2016 to Aug 10, 202364
- Board memberPaolo Pucci Sep 13, 2016 to now65
- Board memberGoldman Myla Lai Feb 21, 2014 to now66
- Board memberWilliam F. Feehery Feb 27, 2012 to now67
- Board memberMark A. Buthman Feb 25, 2011 to now68
- Board memberJohn Weiland May 2, 2007 to Aug 1, 201869
- Board memberThomas W. Hofmann Oct 16, 2007 to now70
- Board memberAnthony Welters Jan 4, 2006 to Apr 4, 201671
- Board memberGeoffrey F. Worden Jan 4, 2006 to May 5, 201172
- Board memberJohn P. Neafsey Jan 4, 2006 to May 5, 201173
- Board memberWilliam H. Longfield Jan 4, 2006 to Apr 11, 200774
- Board memberJenne K. Britell May 4, 2006 to May 7, 200875
- Board memberPatrick J. Zenner May 4, 2006 to Apr 1, 202276
- Board memberPaula Johnson May 4, 2006 to May 7, 202077
- Board memberTenley E. Albright May 4, 2006 to May 4, 200678
Subsidiaries and ownership
Subsidiaries
- West Pharmaceutical Services Deutschland
- West Pharmaceutical Services UK
Also consolidated
Subsidiaries (Exhibit 21)
- TGPR Holdings Limited Ireland7
- Tech Group Europe Limited Ireland7
- Tech Group Grand Rapids, Inc. Delaware7
- West Contract Manufacturing, LLC Delaware7
- West Pharma. Services IL, Ltd. Israel7
- West Pharmaceutical Packaging (China) Company Ltd. China7
- West Pharmaceutical Packaging India Private Limited India7
- West Pharmaceutical Products Ireland, Ltd. Ireland7
- West Pharmaceutical Services AZ, Inc. Arizona7
- West Pharmaceutical Services Argentina S.A. Argentina7
- West Pharmaceutical Services Asia, Ltd. Taiwan7
- West Pharmaceutical Services Australia Pty. Ltd. Australia7
- West Pharmaceutical Services Beograd d.o.o. Serbia7
- West Pharmaceutical Services Brasil Ltda. Brazil7
- West Pharmaceutical Services Colombia S.A.S. Colombia7
- West Pharmaceutical Services Cornwall Limited England7
- West Pharmaceutical Services Danmark ApS Denmark7
- West Pharmaceutical Services Delaware Acquisition, Inc. Delaware7
- West Pharmaceutical Services European Holdings 1 GmbH Germany7
- West Pharmaceutical Services European Holdings II GmbH Germany7
- West Pharmaceutical Services France S.A. France7
- West Pharmaceutical Services Group Limited England7
- West Pharmaceutical Services Hispania S.A. Spain7
- West Pharmaceutical Services Holding GmbH Germany7
All 40 listed subsidiaries
- West Pharmaceutical Services Holding II GmbH Germany7
- West Pharmaceutical Services Holding Ireland North, Ltd. Ireland7
- West Pharmaceutical Services Holding Ireland South, Ltd. Ireland7
- West Pharmaceutical Services Holding Japan, GK Japan7
- West Pharmaceutical Services Holdings Ltd. Israel7
- West Pharmaceutical Services Italia S.r.L. Italy7
- West Pharmaceutical Services Korea, Ltd. South Korea7
- West Pharmaceutical Services Lakewood, Inc. Delaware7
- West Pharmaceutical Services Shanghai Medical Rubber Products Co., Ltd. China7
- West Pharmaceutical Services Singapore Pte. Ltd. Singapore7
- West Pharmaceutical Services Switzerland GmbH In Liquidation Switzerland7
- West Pharmaceutical Services Verwaltungs GmbH Germany7
- West Pharmaceutical Services of Delaware, Inc. Delaware7
- West Pharmaceutical Services of Florida, Inc. Florida7
- West Pharmaceutical Services, Inc. Pennsylvania7
- West Services and Solutions, LLC Delaware7
From Wikidata.1 Ownership links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); each one cites its LEI record. The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Former names
- WEST CO INCApr 5, 1994 to Feb 11, 19996
Timeline
- Sep 10, 2026New chief executive Michel Lagarde becomes CEO18
- Jul 23, 20268-K Results of operations; Regulation FD disclosure79
- Jul 14, 20268-K Entered a material agreement80
- Jun 1, 20268-K Executive or director change; Regulation FD disclosure81
- May 20, 20268-K Cybersecurity incident82
- May 11, 20268-K Cybersecurity incident; Regulation FD disclosure83
- May 5, 20268-K Shareholder vote84
- Apr 23, 20268-K Results of operations; Regulation FD disclosure85
- Mar 9, 20268-K Executive or director change; Regulation FD disclosure86
- Feb 12, 20268-K Results of operations; Regulation FD disclosure87
- Oct 23, 20258-K Results of operations; Regulation FD disclosure88
- Sep 11, 20258-K Executive or director change89
- Jul 24, 20258-K Results of operations; Regulation FD disclosure90
- Apr 27, 2015New chief executive Eric Mark Green becomes CEO19
- Jan 3, 2006New chief executive Donald E. Morel Jr. becomes CEO20
- 1923Founded Founded1
Calendar
Coming up
- Oct 29, 2026 · Before the openReports results for the quarter ending Sep/2026 A year earlier it reported $1.96 a share, on Oct 23, 2025.91
When it reported results
- Jul 23, 2026Reported quarterly or annual results79
- Apr 23, 2026Reported quarterly or annual results85
- Feb 12, 2026Reported quarterly or annual results87
- Oct 23, 2025Reported quarterly or annual results88
- Jul 24, 2025Reported quarterly or annual results90
- Apr 24, 2025Reported quarterly or annual results92
- Feb 13, 2025Reported quarterly or annual results93
- Oct 24, 2024Reported quarterly or annual results94
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
312 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 46 major events, 193 insider forms, 15 large holders, 38 other. The latest 20:
- Oct 2, 20264 EDGAR
- Sep 15, 20264 EDGAR
- Sep 10, 20264 EDGAR
- Sep 10, 20264 EDGAR
- Sep 10, 20263 EDGAR
- Aug 12, 20264 EDGAR
- Aug 6, 2026SCHEDULE 13G EDGAR
- Jul 23, 202610-Q EDGAR
- Jul 23, 20268-K EDGAR
- Jul 14, 20268-K EDGAR
- Jul 1, 20264 EDGAR
- Jun 1, 20268-K EDGAR
- May 20, 20268-K/A EDGAR
- May 14, 20264 PRIMARY DOCUMENT EDGAR
- May 13, 2026SD EDGAR
- May 11, 20268-K EDGAR
- May 7, 2026144 EDGAR
- May 6, 20264 PRIMARY DOCUMENT EDGAR
- May 6, 20264 PRIMARY DOCUMENT EDGAR
- May 6, 20264 PRIMARY DOCUMENT EDGAR
The 312 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
38 open-market trades by officers, directors and large owners since October 2021: 0 buys and 38 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 15, 2026 | Favorite Annette FSr. VP & Chief HR Officer | Sale | 2,524 | $365.00 | $921.3K | Form 4 |
| Sep 14, 2026 | Favorite Annette FSr. VP & Chief HR Officer | Sale | 2,500 | $355.00 | $887.5K | Form 4 |
| Sep 11, 2026 | Favorite Annette FSr. VP & Chief HR Officer | Sale | 2,500 | $345.00 | $862.5K | Form 4 |
| Sep 8, 2026 | Favorite Annette FSr. VP & Chief HR Officer | Sale | 8,135 | $340.81 | $2.8M | Form 4 |
| Apr 27, 2026 | Favorite Annette FSr. VP & Chief HR Officer | Sale | 2,817 | $305.20 | $859.7K | Form 4 |
| Apr 27, 2026 | Winters ChadVP, Chief Accounting Officer | Sale | 896 | $300.67 | $269.4K | Form 4 |
| Oct 29, 2024 | Witherspoon CharlesVP & Treasurer | Sale | 703 | $310.40 | $218.2K | Form 4 |
| Aug 19, 2024 | Witherspoon CharlesVP & Treasurer | Sale | 1,029 | $300.00 | $308.7K | Form 4 |
| Aug 6, 2024 | Green Eric MarkPresident, CEO and Board Chair | Sale | 30,732 | $304.71 | $9.4M | Form 4 |
| Jun 12, 2024 | Abraham SiljiSVP, Chief Technology Officer | Sale | 1,800 | $330.78 | $595.4K | Form 4 |
| May 10, 2024 | Hofmann Thomas WDirector | Sale | 617 | $365.92 | $225.8K | Form 4 |
| May 7, 2024 | Green Eric MarkPresident, CEO and Board Chair | Sale | 66,000 | $366.65 | $24.2M | Form 4 |
| May 7, 2024 | Green Eric MarkPresident, CEO and Board Chair | Sale | 66,000 | $366.65 | $24.2M | Form 4 |
| Mar 11, 2024 | Winters ChadVP, Chief Accounting Officer | Sale | 815 | $358.82 | $292.4K | Form 4 |
| Feb 28, 2024 | Witherspoon CharlesVP & Treasurer | Sale | 2,019 | $358.62 | $724.1K | Form 4 |
| Feb 27, 2024 | Green Eric MarkPresident, CEO and Board Chair | Sale | 64,132 | $359.85 | $23.1M | Form 4 |
| Feb 23, 2024 | Abraham SiljiSVP, Chief Technology Officer | Sale | 7,012 | $365.00 | $2.6M | Form 4 |
| Dec 4, 2023 | Winters ChadVP, Chief Accounting Officer | Sale | 1,013 | $349.00 | $353.5K | Form 4 |
| Dec 1, 2023 | Winters ChadVP, Chief Accounting Officer | Sale | 1,013 | $349.00 | $353.5K | Form 4 |
| Oct 31, 2023 | Witherspoon CharlesVP & Treasurer | Sale | 1,190 | $322.37 | $383.6K | Form 4 |
All 38 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- FMR LLCSCHEDULE 13G, 1 filing Aug 6, 202695
- VANGUARD CAPITAL MANAGEMENT LLCSCHEDULE 13G, 1 filing Apr 30, 202696
- VANGUARD PORTFOLIO MANAGEMENT LLCSCHEDULE 13G, 1 filing Apr 29, 202697
- VANGUARD GROUP INCSCHEDULE 13G/A, 5 filings Feb 10, 2022 to Mar 27, 202698
- PRICE T ROWE ASSOCIATES INC /MD/SC 13G/A, 2 filings Feb 14, 2022 to Feb 14, 202399
- Franklin Templeton InvestmentsSC 13G/A, 1 filing Feb 4, 2022100
SEC filer profile
How West Pharmaceutical Services (United States) is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARWEST PHARMACEUTICAL SERVICES INC2
- CIK0000105770
- Employer ID (EIN)23-121001017
- Filer statusLarge accelerated filer not an emerging growth company; not a smaller reporting company; not a shell company17
- Incorporated inPennsylvania17
- Fiscal year endsDecember 312
- Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus2
- SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance2
- Business address530 Herman O. West Drive, Exton, PA 193412
- Phone61059429002
- Shares outstanding70,375,762 as of Jul 20, 202615
- Public float$15.7B as of Jun 30, 202517
- AuditorPricewaterhouseCoopers LLP, Philadelphia, Pennsylvania PCAOB ID 238; it also attests to the company’s internal control over financial reporting17
- On EDGAR sinceFeb 11, 19942
- Filings3,443 in all: 4 (2,466), 8-K (337), 4/A (113), SC 13G/A (110), 10-Q (98), 3 (44), DEF 14A (33), 10-K (32)2
All 42 form types
11-K (31), SC 13G (27), DEFA14A (17), S-8 (15), SD (13), 8-K/A (12), ARS (11), 144 (10), CT ORDER (7), UPLOAD (7), 10-Q/A (6), 5 (6), CORRESP (6), PRE 14A (5), 3/A (4), S-3/A (4), 10-K/A (3), S-3ASR (3), SCHEDULE 13G (3), SCHEDULE 13G/A (3), S-3 (2), S-8 POS (2), SC TO-I/A (2), 424B3 (1), 424B5 (1), 424B7 (1), 5/A (1), FWP (1), NT 10-K (1), PX14A6G (1), SC 13E4 (1), SC 13E4/A (1), SC TO-C (1), SC TO-I (1)
- Latest filingsAnnual report (10-K) Feb 17, 2026
Quarterly report (10-Q) Jul 23, 2026
Proxy statement (DEF 14A) Mar 12, 2026
Latest 8-K (8-K) Jul 23, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common Stock, par value $.25 per share | WST | New York Stock Exchange |
From the cover page of the 10-K filed Feb 17, 2026 (Section 12(b) of the Exchange Act).17
Risk factors and legal proceedings
The risks West Pharmaceutical Services (United States) names in Item 1A of its 10-K filed Feb 17, 2026: 36 risks under these headings, as written.17
- Many of the factors that will determine our future results are beyond our ability to control or predict. Achievement of future results is subject to known or unknown risks or uncertainties, including, without limitation, the risks set forth below. Therefore, actual results could differ materially from past results and those expressed or implied in any forward-looking statement. You should bear this in mind as you consider forward-looking statements.
- Unless required by applicable securities law, we undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise. We also refer you to further disclosures we make on related subjects in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K to the SEC.
- Global and Economic Risks
- Global economic conditions, including inflation and supply chain disruptions, could adversely affect our operations.
- Unauthorized access to our or our customers’ information and systems could negatively impact our business.
- We are a global company with significant revenues and earnings generated internationally, which exposes us to the impact of foreign currency fluctuations and tariffs, as well as political and economic risks.
- We are exposed to credit risk on accounts receivable and certain prepayments made in the normal course of business. This risk is heightened during periods when economic conditions worsen.
- Unstable market and economic conditions and adverse developments with respect to financial institutions and associated liquidity risk may have serious adverse consequences on our business and financial condition.
- Industry Risks
- Our sales and profitability are largely dependent on the sale of drug products delivered by injection and the packaging of drug products. If the drug products developed by our customers in the future use another delivery system or are reconfigured to require less frequent dosing, our sales and profitability could suffer.
- If we are unable to provide comparative value advantages, timely fulfill customer orders, or resist pricing pressure, we will have to reduce our prices, which may reduce our profit margins.
- Consolidation in the pharmaceutical and healthcare industries could adversely affect our future revenues and operating income.
The other 26 risks
- The medical technology industry is very competitive and customer requests and/or new products in the marketplace could cause a reduction in demand.
- Business and Operational Risks
- Disruption in our manufacturing facilities could have a material adverse effect on our ability to make and sell products and have a negative impact on our reputation, performance or financial condition.
- Our international sales and operations are subject to risks and uncertainties that vary by country and which could have a material adverse effect on our business and/or results of operations.
- Disruptions in the supply of key raw materials could adversely impact our operations.
- Raw material and energy prices have a significant impact on our profitability. If raw material and/or energy prices increase, and we cannot pass those price increases on to our customers, our profitability and financial condition may suffer.
- If we are not timely or successful in new-product innovation or the development and commercialization of proprietary multi-component systems, our future revenues and operating income could be adversely affected.
- We may not succeed in completing divestitures, acquisitions or other strategic transactions, all of which could have an adverse effect on our business and results of operations.
- Product defects could adversely affect the results of our operations.
- A loss of or inability to attract key personnel or highly skilled employees could disrupt our operations.
- The concentration of our customer base could adversely affect our financial condition and operating results.
- We may be unable to increase capacity or efficiency at our own manufacturing facilities, which could adversely affect our business, financial condition, and results of operations.
- Our results of operations and earnings may not meet guidance or expectations.
- No assurance can be given that we will continue to pay or declare dividends.
- If we fail to comply with our obligations under our distributorship or license agreements with Daikyo or the agreements are terminated early or not renewed, we could lose license rights and access to certain product and technology that are important to our business.
- Legal, Regulatory and Compliance Risks
- We are subject to regulation by governments around the world, and if these regulations are not complied with, existing and future operations may be curtailed, and we could be subject to liability.
- Products that incorporate our technologies and medical devices that we produce are subject to regulations and extensive approval or clearance processes, which make the timing and success of new-product commercialization difficult to predict.
- Changes in the regulation of drug products and devices may increase competitive pressure and adversely affect our business.
- If we are not successful in protecting our intellectual property rights, our ability to compete may be affected.
- Significant developments in U.S. tax policies could have a material adverse effect on our business and/or results of operations.
- If we fail to maintain an effective system of internal controls, we may not be able to accurately report our financial results, which could lead to a loss of investor confidence in our financial statements and have an adverse effect on our stock price.
- We are subject to stringent and changing obligations related to data privacy and security. Our actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm and other adverse business consequences.
- Changing climate, global climate change regulations and greenhouse gas effects may adversely affect our operations and financial performance.
- Failure to comply with anti-bribery, anti-corruption and anti-money laundering laws could subject us to penalties and other adverse consequences.
- Our operations must comply with environmental statutes and regulations, and any failure to comply could result in extensive costs which would harm our business.
- Changes in reimbursement practices of third-party payers or other cost containment measures, including changes to applicable laws and regulations, could affect the demand for our products and the prices at which they are sold.
- General Risk Factor
- Our share price has been volatile and may fluctuate, and accordingly, the value of an investment in our common stock may also fluctuate.
Legal proceedings
From time to time, we are involved in various proceedings, lawsuits, disputes and claims arising in the ordinary course of the Company’s business, whether that be matters involving commercial operations, product liability, intellectual property or employment actions, including class action lawsuits. We accrue for loss contingencies when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated based on circumstances and assumptions existing at the time. The outcome of such claims cannot be predicted with certainty and one or more unfavorable outcomes in any claim or litigation against us could have a material adverse effect on our business, financial condition, results of operations or liquidity for the period in which they are resolved.
Securities Class Action
The opening of Item 3, Legal Proceedings.17
Links
- Websitewww.westpharma.com/en/Pages/Default.aspx1
- WikipediaWest Pharmaceutical Services
- WikidataQ30338243
- SEC EDGARCIK 105770
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21SEC EDGAREric Mark Green, Chair
- 22SEC EDGAREric Mark Green, President
- 23SEC EDGARChristopher G. Ryan, President
- 24SEC EDGARKaren Flynn, President
- 25SEC EDGARWarwick Bedwell, President
- 26SEC EDGARJohn E. Paproski, President
- 27SEC EDGARHeino Lennartz, President
- 28SEC EDGARSteven A. Ellers, President
- 29SEC EDGARDonald A. McMillan, President
- 30SEC EDGARRobert S. Hargesheimer, President
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40SEC EDGARCharles Witherspoon, VP & Treasurer
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60SEC EDGARJanet Brutschea Haugen, Board member
- 61SEC EDGARStephen H. Lockhart, Board member
- 62SEC EDGARMolly Joseph, Board member
- 63SEC EDGARDeborah L. Tanner, Board member
- 64SEC EDGAREric Mark Green, Board member
- 65SEC EDGARPaolo Pucci, Board member
- 66SEC EDGARGoldman Myla Lai, Board member
- 67SEC EDGARWilliam F. Feehery, Board member
- 68SEC EDGARMark A. Buthman, Board member
- 69SEC EDGARJohn Weiland, Board member
- 70SEC EDGARThomas W. Hofmann, Board member
- 71SEC EDGARAnthony Welters, Board member
- 72SEC EDGARGeoffrey F. Worden, Board member
- 73SEC EDGARJohn P. Neafsey, Board member
- 74SEC EDGARWilliam H. Longfield, Board member
- 75SEC EDGARJenne K. Britell, Board member
- 76SEC EDGARPatrick J. Zenner, Board member
- 77SEC EDGARPaula Johnson, Board member
- 78SEC EDGARTenley E. Albright, Board member
- 79
- 80SEC EDGAREntered a material agreement
- 81
- 82SEC EDGARCybersecurity incident
- 83
- 84SEC EDGARShareholder vote
- 85
- 86
- 87
- 88
- 89SEC EDGARExecutive or director change
- 90
- 91NasdaqNasdaq calendar
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100